Schizophrenia 1

Summary

Schizophrenia 1 (MONDO:0008414) is a disease and 18 clinical trials. Top therapeutic interventions include fluvoxamine, aripiprazole, and trospium. A subtype of schizophrenia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	schizophrenia 1
Mondo ID	MONDO:0008414
OMIM	181510
DOID	DOID:0070077
UMLS	C0220702
MedGen	65084
Is cancer (heuristic)	no

Also known as: schizophrenia 1 · SCZD1

Disease family

This is a subtype of schizophrenia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › psychotic disorder › schizophrenia › schizophrenia 1

Related subtypes (17): paranoid schizophrenia, treatment-refractory schizophrenia, schizophrenia 3, schizophrenia 5, schizophrenia 7, schizophrenia 8, schizophrenia 2, schizophrenia 10, schizophrenia 11, schizophrenia 12, schizophrenia 15, schizophrenia 16, chromosome 2p16.3 deletion syndrome, early-onset schizophrenia, schizophrenia 19, schizophrenia 17, childhood-onset schizophrenia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	15
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07423546	PHASE1/PHASE2	NOT_YET_RECRUITING	A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
NCT07592169	PHASE2	NOT_YET_RECRUITING	Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia
NCT07550387	PHASE2	COMPLETED	A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
NCT06817980	Not specified	NOT_YET_RECRUITING	Disorders of the Sense of Self and Physical Activity
NCT07144592	Not specified	RECRUITING	The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
NCT07157293	Not specified	NOT_YET_RECRUITING	Online Intervention To Improve Motivation
NCT07242586	Not specified	RECRUITING	PS-Trauma - Development of Trauma Treatment for Patients With Co-morbid Psychotic Disorders and Traumas
NCT07427485	Not specified	ACTIVE_NOT_RECRUITING	Cognitive Rehabilitation With Immersive Virtual Reality (IVR) in Schizophrenia: a Pilot Randomized Waiting List Controlled Feasibility Study
NCT07454200	Not specified	NOT_YET_RECRUITING	Feasibility, Acceptability, and Effectiveness of a Hatha Yoga-in Patients Hospitalized for Schizophrenia
NCT07469384	Not specified	RECRUITING	Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
NCT07559084	Not specified	RECRUITING	Multi-target TMS for Schizophrenia Negative Symptoms
NCT07585656	Not specified	NOT_YET_RECRUITING	Comparison of the Italian and U.S. Forensic Models for Dual-diagnosis Offenders: a 3-year Longitudinal Study
NCT01832285	Not specified	UNKNOWN	Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
NCT07190352	Not specified	COMPLETED	Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia
NCT07371325	Not specified	COMPLETED	Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.
NCT07452835	Not specified	COMPLETED	Transcranial Direct Current Stimulation (tDCS) in Different Psychiatric Disorders
NCT07497516	Not specified	COMPLETED	Mindfulness-Based Yoga in Schizophrenia
NCT07512843	Not specified	COMPLETED	Acceptability and Efficacy of Group Reminiscence Intervention in a Sample of Patients With Schizophrenia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUVOXAMINE	4	3
ARIPIPRAZOLE	4	1
TROSPIUM	4	1
XANOMELINE	4	1